JUNSHI BIO's stock price soared 5.23% during intraday trading on Monday, significantly outperforming the broader biotechnology sector.

The sharp rise was primarily driven by the company's recently released first-quarter 2026 financial results. Junshi Biosciences reported Q1 revenue of 726 million yuan, representing a substantial 45.09% year-over-year increase. More notably, the net loss attributable to the parent company narrowed dramatically by 91.24% to just 20.56 million yuan, while research and development expenditure as a proportion of revenue declined by 31.13 percentage points, signaling significantly improved operational efficiency and a clearer path toward profitability.

While the strong earnings report fueled investor optimism, the company has previously disclosed that two shareholders plan to reduce their combined holdings by a maximum of 2.09%, which may warrant continued attention regarding potential future selling pressure.